Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended December 31, 2025
Business Overview: NeuroOne develops and commercializes thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, monitoring, ablation, and stimulation. The company holds FDA 510(k) clearance for four devices, including the Evo Cortical, Evo sEEG, and OneRF Ablation systems. It operates under a distribution agreement with Zimmer, Inc., which holds exclusive rights to distribute key products. In December 2025, the company initiated a limited market release of its OneRF TN Ablation System.
Key Financial Metrics
| Metric | Q1 2026 (Ended Dec 31, 2025) | Q1 2025 (Ended Dec 31, 2024) |
|---|---|---|
| Product Revenue | $2,892,635 | $3,274,167 |
| License Revenue | $0 | $3,000,000 |
| Total Revenue | $2,892,635 | $6,274,167 |
| Product Gross Profit | $1,567,828 (54.2% margin) | $1,926,889 (58.9% margin) |
| Operating Expenses | $3,275,135 | $3,215,682 |
| Net Loss | $(1,437,890) | $1,785,322 (Net Income) |
| Cash and Cash Equivalents | $3,561,616 | $1,134,350 |
| Working Capital | $6,808,633 | $7,923,201 |
| Warrant Liability | $806,859 | $1,266,894 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 54% compared to the prior year, primarily due to the absence of a $3.0 million one-time license fee recognized in Q1 2025 from the Zimmer distribution agreement. Product revenue declined 12% year-over-year.
- Profitability Shift: The company reported a net loss of $1.44 million, a reversal from a net income of $1.79 million in the prior year. This shift was driven by the loss of license revenue and increased operating expenses.
- Operating Expenses: Total operating expenses increased slightly by $59,453. Research and Development (R&D) expenses rose by $217,452 due to consulting services and materials for drug delivery technology development, partially offset by a decrease in Selling, General, and Administrative (SG&A) expenses.
- Cash Flow: Net cash used in operating activities was $3.12 million, compared to $0.21 million provided by operations in the prior year. The outflow was driven by the net loss and a $1.4 million increase in accounts receivable.
- Warrant Liability: The fair value of the warrant liability decreased by $222,740, providing a non-cash benefit to the income statement.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. With an accumulated deficit of $80.0 million and cash of $3.6 million, the company believes current resources will fund operations only through September 2026. Additional capital raising is required.
- Liquidity Outlook: The company plans to fund operations through existing cash, product revenues, and potential equity or debt financing. Failure to secure additional funding could force a reduction in planned expenditures or cessation of operations.
- Nasdaq Compliance: The company received a 180-day extension from Nasdaq until May 4, 2026, to regain compliance with the minimum bid price requirement ($1.00 per share). Failure to comply may result in delisting.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting due to insufficient segregation of duties. Remediation plans are underway.
- Customer Concentration: For the three months ended December 31, 2025, one customer (Zimmer) accounted for 100% of product revenue.
- Regulatory and Market Risks: Risks include the ability to maintain regulatory clearance, commercialize technology successfully, and the impact of global economic conditions on capital access and supply chain costs.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that $3.6 million in cash will sustain operations through September 2026, given the current burn rate.
- Revenue Sustainability: Assess the reliance on Zimmer for 100% of product revenue and the timeline for the limited market release of the OneRF TN Ablation System to generate meaningful standalone revenue.
- Capital Raising: Monitor upcoming financing activities, as the company explicitly states it may need to raise additional funds to avoid operational constraints.
- Nasdaq Status: Track the stock price to ensure compliance with the $1.00 minimum bid price requirement by May 4, 2026, to avoid delisting.
- Internal Controls: Review future filings for confirmation that the material weakness regarding segregation of duties has been remediated.